May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Clinical Studies of Intravitreal Injection of Bevacizumab (Avastin®) for Rubeosis Associated With Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • H. Sakaguchi
    Dept, Osaka, Suita, Japan
  • Y. Oshima
    Dept, Osaka, Suita, Japan
  • M. Sawa
    Dept, Osaka, Suita, Japan
  • M. Tsujikawa
    Dept, Osaka, Suita, Japan
  • F. Gomi
    Dept, Osaka, Suita, Japan
  • Y. Ikuno
    Dept, Osaka, Suita, Japan
  • M. Kamei
    Dept, Osaka, Suita, Japan
  • S. Kusaka
    Dept, Osaka, Suita, Japan
  • Y. Tano
    Dept, Osaka, Suita, Japan
  • Footnotes
    Commercial Relationships  H. Sakaguchi, None; Y. Oshima, None; M. Sawa, None; M. Tsujikawa, None; F. Gomi, None; Y. Ikuno, None; M. Kamei, None; S. Kusaka, None; Y. Tano, None.
  • Footnotes
    Support  Health Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3841. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Sakaguchi, Y. Oshima, M. Sawa, M. Tsujikawa, F. Gomi, Y. Ikuno, M. Kamei, S. Kusaka, Y. Tano; Clinical Studies of Intravitreal Injection of Bevacizumab (Avastin®) for Rubeosis Associated With Proliferative Diabetic Retinopathy . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3841.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the efficacy and short–term safety of intravitreal injection of bevacizumab (Avastin® ) in patients with rubeosis associated with proliferative diabetic retinopathy.

Design: : Off–label, single–center, uncontrolled clinical study.

Methods: : Intravitreal injection of bevacizumab (1mg) was conducted in a consecutive series of 3 eyes with rubeosis iridis associated with proliferative diabetic retinopathy which poorly responded to laser photocoagulation and vitrectomy. Pre–injection parameters (visual acuity / intraocular pressure [mmHg]) in the 3 eyes were 0.3/30, 0.1/32, and 0.2/14, respectively. Ophthalmic examination, including visual acuity and intraocular pressure measurements, were conducted 1 day, 1 week, and 1 month after injection. Regression of rubeosis was evaluated based on slit–lamp examination with gonioscopy and fluorescein angiography.

Results: : Rubeosis iridis had regressed in 2 eyes (67%) and disappeared completely in 1 eye (33%) from 1 week following injection. Visual acuity remained stable without recurrence of rubeosis and the intraocular pressure was also unchanged for at least 1 month. No inflammation and endophtahlmitis were observed.

Conclusions: : Intravitreal injection of bevacizumab may provide an effective and safe alternative for patients with diabetic rubeosis refractory to conventional treatments.

Keywords: diabetic retinopathy • neovascularization • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.